Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Insight Molecular Diagnostics Inc. Director's Dealing 2021

Jun 14, 2021

34238_dirs_2021-06-14_934ef6da-e683-4038-b436-1547e84d6e44.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2021-06-11

Reporting Person: Last Andrew J. (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-11 Common Stock X 6993 $3.00 Acquired 30170 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-11 Warrants $3.00 X 6993 Acquired 2024-02-01 Common Stock (6993) Direct